Abstract
Bentazepam (BTZ), 75 mg/day, and ketazolam (KZ), 30 mg/day, were compared in a parallel, randomized, non-blind study conducted with 40 outpatients diagnosed with anxiety disorders according to the Diagnostic and Statistical Manual of Mental Disorders, revised third edition. After a 1-week washout period to anxiolytic drugs, patients were assigned to either BTZ (n = 20) or KZ (n = 20) treatment. Both the Hamilton Anxiety Rating Scale (HARS) and State subscale from the State-Trait Anxiety Inventory of Spielberger (STAI-S) were administered at baseline and at weeks 1, 3, and 6 of treatment. The Digit-Symbol Substitution Test (DSST) and Digit Span (DS) were performed at every evaluation. Treatment with both BTZ and KZ reduced anxiety as measured by decreases in HARS and STAI-S scores during the study. Small differences in favor of BTZ were reported at week 3 of treatment. Neither drug had a major influence on results from the cognitive tests (DSST and DS).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
